Article

Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.

U.O. Oncologia and Pneumologia, AOS-S. Maria degli Angeli, via Montereale 24, 33170 Pordenone, Italy.
Lung Cancer (impact factor: 3.43). 01/2002; 34 Suppl 4:S37-46. pp.S37-46
Source: PubMed

ABSTRACT In the last years, the main topoisomerase I inhibitors (TP1-I) (i.e. topotecan and irinotecan) have been used in combination chemotherapy in non-small cell lung cancer. Several drugs (also alternative to cisplatin) have been used in combination with TP1-I, but to date the higher remission rate obtained with combinations is not translated into a more prolonged survival in comparison with TP1-I given alone. On the other hand, the toxicity of TP1-I combinations is greater than those of TP1-I used alone. The superior efficacy of combinations versus TP1-I used alone remains an open question. Furthermore, the best schedule for TP1-I has not been completely elucidated. Randomised studies are few (only two phase III trials) and only controlled studies will be able to clarify the best TP1-I combination regimen.

0 0
 · 
0 Bookmarks
 · 
14 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

combination chemotherapy
 
drugs
 
last years
 
main topoisomerase
 
non-small cell lung cancer
 
open question
 
phase III trials
 
prolonged survival
 
Randomised studies
 
superior efficacy
 
topotecan
 
TP1-I
 
TP1-I combination regimen
 
TP1-I combinations
 

S Tumolo